Vivos Therapeutics Plans Rights Offering to Raise Capital
Event summary
- Vivos Therapeutics intends to file a registration statement with the SEC for a proposed rights offering.
- Each right is expected to entitle holders to purchase one share of Vivos common stock at an exercise price of $1.25 per share or 20% above the market price on the day before the record date.
- The rights will be exercisable for a period of nine months, with a subsequent 'exploding' right upon exercise.
- The proposed rights offering is subject to multiple conditions, including SEC approval and shareholder vote.
The big picture
Vivos Therapeutics' proposed rights offering is a strategic move to secure additional capital for operations and general corporate purposes. This comes amid a landscape where obstructive sleep apnea (OSA) treatments are evolving, with Vivos' innovative devices aiming to address the root causes of OSA. The success of this offering will depend on regulatory approvals and market conditions, highlighting the company's need to navigate both financial and operational challenges.
What we're watching
- Regulatory Approval
- Whether the SEC will declare the registration statement effective and the timing of such approval.
- Market Conditions
- How prevailing market conditions will impact the success and terms of the rights offering.
- Shareholder Participation
- The level of participation by shareholders and the amount of proceeds ultimately realized from the offering.
Related topics